- Recce Pharmaceuticals (RCE) has lodged an application to commence human clinical trials for its topical burns treatment, RECCE 327
- The ASX-lister announced it had registered for the trial with the Australian and New Zealand Clinical Trial Registry for a phase I/II topical burns study
- The study is set to test 30 patients over two weeks in a bid to test the efficacy of the drug
- In a broader context, Recce said the application represents one of the final administration stages required before the trial can commence
Read the full article on the Market Herald here
Recce Pharmaceuticals makes first steps towards new trials
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.005(1.67%) |
Mkt cap ! $85.06M | |||
| Open | High | Low | Value | Volume |
| 29.5¢ | 29.5¢ | 29.0¢ | $38.76K | 133.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 135000 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 9819 | 2 |
View Market Depth
| Last trade - 16.10pm 23/06/2025 (20 minute delay) ? |
| RCE (ASX) Chart |